Asian Federation of Osteoporosis Societies (AFOS 2017) 5th Annual Scientific Meeting

Malaysia
Search
Sign In

Obstetrics & Gynaecology Search

Obstetrics & Gynaecology

Obstetrics & Gynaecology

Home News Diseases Conferences Special Reports Multimedia

Asian Federation of Osteoporosis Societies (AFOS 2017) 5th Annual Scientific Meeting

06 October 2017 - 08 October 2017

$Denosumab: Antiresorptive agent reduces fracture risk$

Denosumab: Antiresorptive agent reduces fracture risk

Jairia Dela Cruz, 20171222100000

The monoclonal antibody denosumab demonstrates potent antiresorptive effect in the treatment of osteoporosis, conferring benefit for fracture risk and averting bone loss in select oncological situations. The drug must be used without interruption to prevent a rebound effect, according to Dr Tai-Pang Ip, a consultant endocrinologist from Hong Kong who spoke at AFOS 2017 held in Kuala Lumpur, Malaysia.

Balancing risks and benefits of bisphosphonates

Pearl Toh, 20171021110010

Bisphosphonate is one of the first-line therapy for treating osteoporosis, but its long-term use should take into account the balance between its antifracture benefit and risk of adverse events such as atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), according to a presentation at the AFOS 2017 Meeting in Kuala Lumpur, Malaysia.

Trabecular bone score not lower in T2D

Roshini Claire Anthony, 20171017140300

Patients with type 2 diabetes (T2D) may not necessarily have lower trabecular bone scores (TBS) than nondiabetics, a finding that contrasts with that of previous research, according to a study published in a poster at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia.

Drug holiday for osteoporosis: Who, when, how long?

Elvira Manzano, 20171017110000

Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.

Functional imaging modalities enhance localization of tumour-induced osteomalacia

Audrey Abella, 20171017090000

The use of functional imaging modalities such as octreotide scintigraphy and 68Ga DOTATATE PET/CT* enhances localization of tumour-induced osteomalacia (TIO), a rare syndrome characterized by bone pain, muscle weakness, and skeletal deformities due to overproduction of the hormone fibroblast growth factor 23 (FGF23), according to data presented at AFOS 2017.

Slideshow: Highlights from the Asian Federation of Osteoporosis Societies (AFOS 2017) 5th Annual Scientific Meeting

20171017000000

Slideshow: Highlights from the Asian Federation of Osteoporosis Societies (AFOS 2017) 5th Annual Scientific Meeting

Genetic advances in osteoporosis: What's next?

Elvira Manzano, 20171016142000

Osteoporosis is an age-related complex disease with a strong genetic component. However, the genes responsible for the disease remain poorly defined, says an expert at AFOS 2017.

Treatment failure in osteoporosis: What can be done?

Roshini Claire Anthony, 20171016140300

Treatment failure in osteoporosis remains a problem, even among patients who are treatment-adherent, according to a presentation at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia.

1 in 4 men has osteoporosis, yet most underdiagnosed

Pearl Toh, 20171016100010

About one in four men in the Philippines had osteoporosis but many were underdiagnosed, with old age (>70 years), history of fracture, and family history of osteoporosis being the main risk factors of developing the condition, according to a study presented at the AFOS 2017 Annual Meeting.

Balloon kyphoplasty safe, effective for OVF with middle column compromise

Stephen Padilla, 20171016080000

Elderly patients with osteoporotic vertebral fractures (OVF) should refrain from undergoing highly invasive surgery, but those with no posterior wall mobility or paralysis may benefit from balloon kyphoplasty (BKP) for OVF with posterior vertebral wall damage, according to a study presented at the 5th Scientific Meeting Asian Federation of Osteoporosis Societies (AFOS) 2017 in Kuala Lumpur, Malaysia.

Slideshow: Highlights from the Asian Federation of Osteoporosis Societies (AFOS 2017) 5th Annual Scientific Meeting

Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!

No benefit to adding ibandronate to hormonal therapy in postmenopausal breast cancer

Roshini Claire Anthony, 14 Dec 2016

The addition of ibandronate to adjuvant hormonal therapy provides no benefit to postmenopausal women with HR-positive breast cancer, according to early results from the phase III TEAM IIB trial (BOOG 2006-4)*.